The HEALEY ALS Platform Trial announces first participants enrolled for investigational product SLS-005 (Trehalose)
First participants for the investigational product SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion).
Dr. Paganoni is an Associate Professor at Harvard Medical School and works as a physician scientist at the Healey Center for ALS at Massachusetts General Hospital and at Spaulding Rehabilitation Hospital.Her research focuses on clinical trials and therapy development for ALS. She has served as PI of several ALS clinical trials and has been using novel trial designs, novel endpoints and digital technology tools to innovate the way investigational products are tested in ALS. She is the co-PI of the HEALEY ALS Platform Trial, the first platform trial for ALS in the world. She recently reported the positive results of the CENTAUR trial and is the co-Chair of the global PHOENIX trial.She is also working with people with Primary Lateral Sclerosis (PLS), a rare form of Motor Neuron Disease, and Hereditary Spastic Paraplegia (HSP). She co-chairs the PLS Task Force and the PLS registry of the Northeast ALS Consortium (NEALS). She is working with other Harvard researchers on developing new assistive technology devices that can improve function and quality of life for people with ALS and other forms of Motor Neuron Disease. Dr. Paganoni published >100 peer-reviewed papers. She is an editorial board member for Muscle and Nerve and the American Journal of PM&R where she is also Associate Editor for the Section Evidence-Based Physiatry/Cochrane Corner. Her research has been funded by the NIH, foundations, and industry. She received several awards for her work including the NIH Rehabilitation Medicine Scientist Training Program Award (2012), the American Academy of Neurology / ALS Association Three-Year Career Development Award in ALS (2017), the American Association of Neuromuscular & Electrodiagnostic Medicine Scientific Impact Award (2019), the Top 10 Clinical Research Achievement Award (2021), and the Martin Prize for Excellence in Clinical Research Award (2021).Dr. Paganoni holds 3 Board Certifications (Physical Medicine and Rehabilitation, Neuromuscular Medicine, and Electrodiagnostic Medicine). She is a member of the Association of Academic Physiatrists (AAP), American Academy of Neurology (AAN), and American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM).
Departments, Centers, & Programs:
Clinical Interests:
Treats:
Languages:
Sean M. Healey and AMG Center for ALS
55 Fruit Street
Wang Ambulatory Care Center
8th Floor
Boston, MA 02114
Phone: 617-724-3914
Medical Education
American Board Certifications
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
Mass General is recognized as a top hospital on the U.S. News Best Hospitals Honor Roll for 2025-2026.
Collaboration between Healey Center investigator Sabrina Paganoni, MD, PhD and Amylyx Pharmaceuticals has created promising results for patients.
First participants for the investigational product SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion).
First of its kind trial design expedites drug testing and expands patient access to new investigational products.
The Cullen Education and Research Fund (CERF) announced the recipients of the first CERF Medical Engineering Prize for ALS Research: Leigh Hochberg, MD, PhD; Conor Walsh, PhD; and Sabrina Paganoni, MD, PhD.
The independent Data and Safety Monitoring Board (DSMB) recommended stopping the zilucoplan regimen in the HEALEY ALS Platform Trial after a pre-scheduled interim analysis demonstrated futility.
The Healey Center at MGH and the Northeast ALS (NEALS) Consortium launched the first platform trial for amyotrophic lateral sclerosis (ALS), in which multiple treatments are tested and evaluated simultaneously to accelerate the development of therapies for people with ALS.
Drug will be tested simultaneously with multiple treatments in novel, accelerated trial format

Reviews: Comments and Ratings